Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NAVB | US
0
0%
Healthcare
Biotechnology
30/09/2023
21/10/2024
0.00
0.00
0.00
0.00
Navidea Biopharmaceuticals Inc. a biopharmaceutical company focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities including single photon emission computed tomography positron emission tomography (PET) gamma-scanning and intra-operative and/or optical-fluorescence detection as well as delivery of therapeutic compounds that target macrophages and immune-and inflammation-involved diseases. It develops NAV3-31 which has completed Phase IIb clinical trials for evaluating imaging repeatability reproducibility and stability as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33 which is in Phase III clinical trial for RA; and NAV3-32 which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular kaposi's sarcoma tuberculosis and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals Inc. in January 2012. Navidea Biopharmaceuticals Inc. was incorporated in 1983 and is headquartered in Dublin Ohio.
View LessLow Debt to Equity (< 0.25)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
0.0%1 month
0.0%3 months
0.0%6 months
114.8%-
-
8.16
-0.38
0.22
-0.54
509.67
-
-10.13M
100.08K
100.08K
-
-1.68M
-
-98.80
-1.10K
0.52
3.96
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0
Range1M
0.13
Range3M
0.13
Rel. volume
0.01
Price X volume
0.15
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
U.S. Stem Cell Inc | USRM | Biotechnology | 0.0001 | 64.15K | 0.00% | n/a | -60.68% |
EFTR | EFTR | Biotechnology | 0.0012 | 5.64K | 0.00% | n/a | 2315.36% |
Calithera Biosciences Inc | CALA | Biotechnology | 0.001 | 4.87K | -50.00% | n/a | 8.17% |
OCEAW | OCEAW | Biotechnology | 0.0398 | 0 | 2.58% | n/a | -16.02% |
Nutriband Inc. Warrant | NTRBW | Biotechnology | 1.15 | 0 | 9.52% | n/a | 1.72% |
NKGen Biotech Inc. Warrants | NKGNW | Biotechnology | 0.032 | 0 | 29.03% | n/a | -40.33% |
JSPRW | JSPRW | Biotechnology | 0.21 | 0 | 0.00% | n/a | 2.31% |
ICUCW | ICUCW | Biotechnology | 0.039 | 0 | 0.52% | n/a | -45.50% |
Humacyte Inc | HUMAW | Biotechnology | 1.8999 | 0 | 5.55% | n/a | -63.37% |
EyeGate Pharmaceuticals Inc | EYEG | Biotechnology | 36.05 | 0 | -0.92% | n/a |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
No data |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.54 | 0.53 | Cheaper |
Ent. to Revenue | 509.67 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 8.16 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | - | 72.80 | - |
Debt to Equity | -0.38 | -1.23 | Expensive |
Debt to Assets | 0.22 | 0.25 | Par |
Market Cap | 100.08K | 3.66B | Emerging |